Diarrhea
Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
Published in Vaccine Weekly, May 28th, 2008
Intercell AG (VSE: ICLL) and Iomai Corporation (NASDAQ:IOMI) announced that they have entered into a definitive agreement pursuant to which Intercell will acquire Iomai for USD 6.60 per share representing a fully diluted equity value of approximately USD 189 million (EUR 122 million). The transaction has been unanimously approved by the Boards of Directors of both companies and is subject to customary closing conditions including antitrust clearances, clearance by the Committee on Foreign Investment in the United States and the approval of the holders of a majority of Iomai's shares. Shareholders holding over 50 percent of Iomai's total shares outstanding have entered into agreements to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2008-05-28)
More Articles from Vaccine Weekly
- DOE/Brookhaven National Laboratory
Scientists determine drug target for the most potent botulinum neurotoxin - Emory University
Researchers find first conclusive evidence of Alzheimer's-like brain tangles in nonhuman primates - Anthrax
Studies from Harvard University, Medical Department update current data on anthrax - Cancer Gene Therapy
Research in the area of cancer gene therapy reported from M.E. Mossoba and colleagues - Flu Vaccines
Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial - Human Papillomavirus Vaccines
New findings reported from Florida State University, Medical Department describe advances in human papillomavirus vaccines - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
